Table 2.
Medication use and exposure to PIMs
| Pre-intervention (n = 137) | Post-intervention (n = 132) | p-value | |
|---|---|---|---|
| PIM exposurea | |||
| Prevalence of ≥1 PIM use admission vs discharge, n (%) | 74.5% vs 75.2% | 72.0% vs 72.7% | 0.65 |
| Admission vs discharge, mean (SD) | 1.6 (1.6) vs 1.6 (1.6) | 1.6 (1.5) vs 1.5 (1.4) | 0.36 |
| Deprescribing of PIMs | |||
| At least one PIM ceased, n (%) | 19 (13.9) | 24 (18.2) | 0.34 |
| At least one PIM dose reduced, n (%) | 7 (5.1) | 6 (4.5) | 0.83 |
| Reduction in total PIMs at discharge, n (%) | 15 (10.9) | 18 (13.6) | 0.50 |
| Regular medications | |||
| Admission vs discharge, mean (SD) | 7.3 (3.1) vs 7.9 (3.2) | 9.5 (4.9) vs 10.7 (4.4) | 0.014 |
| At least one medication ceased, n (%) | 49 (35.8) | 60 (45.5) | 0.11 |
| At least one medication dose reduced, n (%) | 26 (19.0) | 36 (27.3) | 0.11 |
PIM potentially inappropriate medication, SD standard deviation
aCreatinine clearance was unable to be calculated in 10 of 137 participants in the pre-intervention cohort and 32 of 132 participants in the post-intervention cohort because of weight not being recorded. Any PIMs related to creatinine clearance were not assessed in these patients